Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced expanded capabilities that enable clinicians to use its advanced clinical chatbot Gia to guide their patients in an intuitive, enjoyable and telemedicine-friendly conversation through receiving and understanding genetic test results and possible next steps, including scheduling a call with a genetics counselor.
“While the pandemic brought new urgency to the need for telemedicine-friendly patient tools, we’ve known for a long time that Gia can make the genetic testing process easier and more accessible for both patients and clinicians,” said Moran Snir, co-developer of Gia and head of experience platform at Invitae. “By adding support for returning results to Gia’s capabilities, we can help reduce delays caused by wait lists for in-person appointments and hours of travel to appointments, while freeing up genetic counselors to provide intensive counseling and support for patients who need it. These kinds of tools are essential for helping more clinicians incorporate genetics into routine clinical care for their patients.”
Gia provides an industry-leading patient genetics chatbot experience. The chatbot is integrated into software that supports clinical workflow throughout the genetic testing process, from pretest education to family history gathering and ordering support and continuing through post-test education. Coupled with Invitae’s full suite of software solutions that provide comprehensive workflow support, a wide variety of clinicians such as obstetrician/gynecologists, oncologists and genetic counselors can use Gia to help them integrate routine genetic testing into patient care. Importantly, chatbot technology also helps clinicians overcome disparities in access to genetic information by addressing language and socioeconomic barriers.
Gia, which stands for “genetic information assistant,” was designed in partnership with genetic counselors to help streamline communication between patients and clinicians. Launched in 2017 and deployed by major academic health systems, the platform has helped more than 100,000 patients with pretest education and intake and post-test counseling. Gia is HIPAA-compliant and has a 92% satisfaction rate among patients. Gia is available to clinicians in the United States.
To learn more, visit www.invitae.com/gia.
Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae’s goal is to aggregate the world’s genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company’s website at invitae.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the benefits and capabilities of Gia. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company’s history of losses; the company’s ability to compete; the company’s failure to manage growth effectively; the company’s need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the company’s ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company’s business; and the other risks set forth in the company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.
The original article can be found at: BioSpace